These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

714 related articles for article (PubMed ID: 22961628)

  • 1. Mdm2 antagonists induce apoptosis and synergize with cisplatin overcoming chemoresistance in TP53 wild-type ovarian cancer cells.
    Mir R; Tortosa A; Martinez-Soler F; Vidal A; Condom E; Pérez-Perarnau A; Ruiz-Larroya T; Gil J; Giménez-Bonafé P
    Int J Cancer; 2013 Apr; 132(7):1525-36. PubMed ID: 22961628
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pre-clinical efficacy and synergistic potential of the MDM2-p53 antagonists, Nutlin-3 and RG7388, as single agents and in combined treatment with cisplatin in ovarian cancer.
    Zanjirband M; Edmondson RJ; Lunec J
    Oncotarget; 2016 Jun; 7(26):40115-40134. PubMed ID: 27223080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Periostin in tumor microenvironment is associated with poor prognosis and platinum resistance in epithelial ovarian carcinoma.
    Sung PL; Jan YH; Lin SC; Huang CC; Lin H; Wen KC; Chao KC; Lai CR; Wang PH; Chuang CM; Wu HH; Twu NF; Yen MS; Hsiao M; Huang CY
    Oncotarget; 2016 Jan; 7(4):4036-47. PubMed ID: 26716408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Akt promotes cisplatin resistance in human ovarian cancer cells through inhibition of p53 phosphorylation and nuclear function.
    Fraser M; Bai T; Tsang BK
    Int J Cancer; 2008 Feb; 122(3):534-46. PubMed ID: 17918180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1.
    Ambrosini G; Sambol EB; Carvajal D; Vassilev LT; Singer S; Schwartz GK
    Oncogene; 2007 May; 26(24):3473-81. PubMed ID: 17146434
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overexpression of HIPK2 circumvents the blockade of apoptosis in chemoresistant ovarian cancer cells.
    Puca R; Nardinocchi L; Pistritto G; D'Orazi G
    Gynecol Oncol; 2008 Jun; 109(3):403-10. PubMed ID: 18395248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Down-regulation of X-linked inhibitor of apoptosis protein induces apoptosis in chemoresistant human ovarian cancer cells.
    Sasaki H; Sheng Y; Kotsuji F; Tsang BK
    Cancer Res; 2000 Oct; 60(20):5659-66. PubMed ID: 11059757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53.
    Van Maerken T; Ferdinande L; Taildeman J; Lambertz I; Yigit N; Vercruysse L; Rihani A; Michaelis M; Cinatl J; Cuvelier CA; Marine JC; De Paepe A; Bracke M; Speleman F; Vandesompele J
    J Natl Cancer Inst; 2009 Nov; 101(22):1562-74. PubMed ID: 19903807
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chaetoglobosin K induces apoptosis and G2 cell cycle arrest through p53-dependent pathway in cisplatin-resistant ovarian cancer cells.
    Li B; Gao Y; Rankin GO; Rojanasakul Y; Cutler SJ; Tu Y; Chen YC
    Cancer Lett; 2015 Jan; 356(2 Pt B):418-33. PubMed ID: 25304379
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The MDM2-inhibitor Nutlin-3 synergizes with cisplatin to induce p53 dependent tumor cell apoptosis in non-small cell lung cancer.
    Deben C; Wouters A; Op de Beeck K; van Den Bossche J; Jacobs J; Zwaenepoel K; Peeters M; Van Meerbeeck J; Lardon F; Rolfo C; Deschoolmeester V; Pauwels P
    Oncotarget; 2015 Sep; 6(26):22666-79. PubMed ID: 26125230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic potential of Mdm2 inhibition in malignant germ cell tumours.
    Bauer S; Mühlenberg T; Leahy M; Hoiczyk M; Gauler T; Schuler M; Looijenga L
    Eur Urol; 2010 Apr; 57(4):679-87. PubMed ID: 19560254
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Restoration of p53 pathway by nutlin-3 induces cell cycle arrest and apoptosis in human rhabdomyosarcoma cells.
    Miyachi M; Kakazu N; Yagyu S; Katsumi Y; Tsubai-Shimizu S; Kikuchi K; Tsuchiya K; Iehara T; Hosoi H
    Clin Cancer Res; 2009 Jun; 15(12):4077-84. PubMed ID: 19509161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disruption of the MDM2-p53 interaction strongly potentiates p53-dependent apoptosis in cisplatin-resistant human testicular carcinoma cells via the Fas/FasL pathway.
    Koster R; Timmer-Bosscha H; Bischoff R; Gietema JA; de Jong S
    Cell Death Dis; 2011 Apr; 2(4):e148. PubMed ID: 21509038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclin-dependent kinase inhibitors sensitize tumor cells to nutlin-induced apoptosis: a potent drug combination.
    Cheok CF; Dey A; Lane DP
    Mol Cancer Res; 2007 Nov; 5(11):1133-45. PubMed ID: 18025259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cisplatin in Combination with MDM2 Inhibition Downregulates Rad51 Recombinase in a Bimodal Manner to Inhibit Homologous Recombination and Augment Tumor Cell Kill.
    Xie X; He G; Siddik ZH
    Mol Pharmacol; 2020 Apr; 97(4):237-249. PubMed ID: 32063580
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Musashi-2 is a novel regulator of paclitaxel sensitivity in ovarian cancer cells.
    Lee J; An S; Choi YM; Lee J; Ahn KJ; Lee JH; Kim TJ; An IS; Bae S
    Int J Oncol; 2016 Nov; 49(5):1945-1952. PubMed ID: 27600258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of p53 in cisplatin-resistant ovarian cancer cell lines: modulation with the novel platinum analogue (1R, 2R-diaminocyclohexane)(trans-diacetato)(dichloro)-platinum(IV).
    Hagopian GS; Mills GB; Khokhar AR; Bast RC; Siddik ZH
    Clin Cancer Res; 1999 Mar; 5(3):655-63. PubMed ID: 10100719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disruption of p73-MDM2 binding synergizes with gemcitabine to induce apoptosis in HuCCT1 cholangiocarcinoma cell line with p53 mutation.
    Zheng T; Wang J; Chen X; Meng X; Song X; Lu Z; Jiang H; Liu L
    Tumour Biol; 2010 Aug; 31(4):287-95. PubMed ID: 20422343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of the p53 pathway by the MDM2 inhibitor nutlin-3a overcomes BCL2 overexpression in a preclinical model of diffuse large B-cell lymphoma associated with t(14;18)(q32;q21).
    Drakos E; Singh RR; Rassidakis GZ; Schlette E; Li J; Claret FX; Ford RJ; Vega F; Medeiros LJ
    Leukemia; 2011 May; 25(5):856-67. PubMed ID: 21394100
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of p53 by Nutlin-3a, an antagonist of MDM2, induces apoptosis and cellular senescence in adult T-cell leukemia cells.
    Hasegawa H; Yamada Y; Iha H; Tsukasaki K; Nagai K; Atogami S; Sugahara K; Tsuruda K; Ishizaki A; Kamihira S
    Leukemia; 2009 Nov; 23(11):2090-101. PubMed ID: 19710698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.